

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

Rec'd

T/PTC



19 SEP 2004

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/38		(11) International Publication Number: WO 95/05170
A1		(43) International Publication Date: 23 February 1995 (23.02.95)
(21) International Application Number: PCT/US94/09011 (22) International Filing Date: 9 August 1994 (09.08.94) (30) Priority Data: 08/106,505 13 August 1993 (13.08.93) US (71) Applicant: WARNER-LAMBERT COMPANY [US/US]; 2800 Plymouth Road, Ann Arbor, MI 48105 (US). (72) Inventors: CONNOR, David, Thomas; 2453 Antietam, Ann Arbor, MI 48105 (US). GRACHECK, Stephen, Joseph; 4730 Whitman Circle, Ann Arbor, MI 48103 (US). POST, Leonard, E.; 3695 Pheasant Drive, Ann Arbor, MI 48103 (US). (74) Agents: ASHBROOK, Charles, W.; Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105 (US) et al.		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS OF INHIBITING HIV AND INHIBITING THE ACTIVATION OF HIV		
(57) Abstract The present invention discloses compounds which substantially inhibit HIV or the activation of HIV in HIV-infected individuals. The compounds, their derivatives, and pharmacologic salts may be formulated into a pharmacologic agent to treat HIV infections. These pharmacologic agents may be used to treat immunosuppression, and other diseases of the immune system. The present invention also provides methods for preparing the compounds and formulating the compounds into pharmacologic agents.		

BEST AVAILABLE COPY

DOCKET NO. T1P28USAPCT FILED: 09/08/2004
1st INVENTOR: Marie Pierre T.M.M.G. DE BETHUNE

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

METHODS OF INHIBITING HIV AND INHIBITING
THE ACTIVATION OF HIV

5

FIELD OF THE INVENTION

The present invention discloses a series of known compounds which substantially inhibit the human immunodeficiency virus (HIV) and inhibit the activation
10 of HIV in HIV-infected individuals. In addition, the present invention provides methods of using these compounds as immunosuppressives and for the treatment of other diseases of the immune system. These compounds are also useful for the preparation of
15 pharmaceutical compositions for use as inhibitors of HIV, inhibitors of the activation of HIV in HIV-infected individuals, as immunosuppressives, and for the treatment of other diseases of the immune system.

20

BACKGROUND

The pathogenesis of the human immunodeficiency virus (HIV) is complicated and as of yet not completely
25 understood. The virus life cycle has theoretically been divided into afferent and efferent components. Virus binding, fusion, reverse transcription, and finally integration are among those events which
30 encompass the afferent component of the life cycle. It is the afferent component of the HIV life cycle which is responsible for primary infection of HIV in an individual, generally followed by a burst of viraemia with or without clinical symptoms.

35

Many therapeutic strategies have been developed and targeted for intervention during the afferent

-2-

events. See for example, Mitsuya H and Broder S:
Inhibition of the in vitro infectivity and cytopathic
effect of human T-lymphotropic virus type III/
Lymphadenopathy virus-associated virus (HTLV-III/LAV)
5 by 2', 3'-dideoxynucleosides, Proc. Natl. Acad. Sci.
(USA) 1986;83:1911-1915.

Whereas different stages of the afferent component
offer the potential for effective therapeutic
intervention, it has become increasingly apparent that
10 intervention solely at these points is insufficient.
After becoming infected with HIV and the disease
progresses through the afferent stages, an individual
experiences a prolonged period of clinical latency
which may extend for several years and the individual
15 remains in good health. At this point in time, low to
absent levels of viraemia and virus replication in
peripheral blood cells are achieved. At a later point,
however, the disease eventually progresses to life-
threatening constellation of disease and
20 immunosuppression (AIDS) for which there remains no
cure. These later events are the clinical
manifestations of the efferent stages of HIV infection.

The efferent component of the HIV life cycle
includes those events necessary for the HIV provirus to
25 successfully transcribe, translate, assemble, and
produce virions. Onset of the events necessary for
HIV-infected cells to progress from an asymptomatic,
non-HIV expressive stage to a symptomatic, HIV
expressive stage is referred to as activation.
30 Presently, the efferent component and the cellular
basis for activation is not completely understood.
Nevertheless, if novel therapeutic agents and
strategies are developed and implemented during the
clinically asymptomatic phase to fight the progression
35 toward AIDS, some hope may be afforded the estimated

-3-

one million infected, but clinically asymptomatic individuals.

Attempts at understanding the virologic and cellular basis for the clinical asymptomatic period reveal that HIV exists as a dormant or nonexpressing provirus in a reservoir population of chronically infected cells. A specific type of HIV, HIV-1, has been the subject of a number of different research projects which have shown that the virus exists as a dormant or nonexpressing provirus in a reservoir population of chronically infected T-lymphocytic cells. Greater detail concerning the nuclear and biochemical mechanisms responsible for maintaining the nonexpressive viral state, however, is beyond the scope of this review, but can be found in detail elsewhere. Mechanisms of HIV-1 Latency, Bednarik, et al., AIDS 1992;6:3-16.

Until recently, it was believed that HIV was dormant or nonexpressing in all the reservoir population of chronically infected cells during the clinical asymptomatic period. Observations of the low to absent levels of viraemia and virus replication in peripheral blood cells led to the impression that HIV disease was not active during the clinical asymptomatic period. A team of scientists, however, have discovered that a true state of microbiological latency does not exist during the course of HIV infection. Fauci AS, et al., HIV Infection is Active and Progressive in Lymphoid Tissue During the Clinically Latent Stage of disease, Nature 1993;362:355-358.

The scientists reported a dichotomy between the levels of viral burden and virus replication in peripheral blood versus lymphoid organs during clinical latency. Based on these findings, therefore, the scientists have discovered that "peripheral blood does not accurately reflect the actual state of HIV disease,

-4-

particularly early in the clinical course of HIV infection. In fact, HIV disease is active and progressive even when there is little evidence of disease activity by readily measured viral parameters in the peripheral blood, and the patient is
5 experiencing clinical latency."

Inevitably, the disease state of HIV progresses from the clinically latent asymptomatic period to the expressive and active symptomatic period. Through the
10 use of several different models, an understanding of the cellular pathways involved in HIV activation from laboratory latency has begun to unfold. According to Butera, et al., AIDS 1992;6:994, many of the cellular models of latency can be induced to express HIV-1 upon
15 treatment with cytokines. This indicates that in the state of microbiologic latency, HIV-1 awaits an extracellular stimulus before initiating replication. This signal not only can be mediated through a soluble cytokine interaction with its receptor, but also
20 through receptor-receptor interactions which occur during cell to cell communication or cellular stress such as UV light exposure and heat shock. Furthermore, an extracellular induction signal can be generated in an autocrine or paracrine fashion so that an HIV-1
25 activated cell can propagate its own expression while activating a nearby latent cell.

Additional factors have been considered by those of skill in the art to be involved in the activation of HIV. One study has shown that 12-O-tetradecanoyl-
30 phorbol-13-acetate (TPA) mediates CD4 down regulation and viral expression in HIV-infected cells. Hamamoto, et al., Biochem. Biophys. Res. Commun. 1989;164:339-344. Interestingly, Hamamoto also examined the effect of the potent protein kinase C
35 inhibitors staurosporine, H-7, and UCN-01 on TPA-mediated CD4 down regulation and augmentation of HIV

-5-

expression. Staurosporine was found to be an effective TPA inhibitor for both of these actions.

5 The cellular pathways involved in mediating the activating signal from the plasma membrane to the integrated virus, resulting in HIV-1 expression, are much less clear. Recently, the development of a reliable and simple system for evaluating compounds that could prevent activation of latent HIV was reported at the National Cooperative Discovery Grant
10 (NCDDG)/AIDS by P. Feorino, S. T. Butera, T. M. Folks, and R. F. Schinazi, San Diego, CA, November 3-7, 1991. The assay system employed the OM-10.1 cell line, a unique chronically-infected promyelocytic clone which remains CD4+ until HIV-1 activation with tumor necrosis
15 factor- α . The expression of CD4+ on the cell surface and the activity of reverse transcriptase are used as markers for quantitating viral expression. Alternatively, other HIV markers, such as protease activity, which are known to those of skill in the art can be used. OM-10.1 cells remain CD4+ until viral
20 activation and respond to tumor necrosis factor induction, and therefore, these cultures are used to conveniently and rapidly examine pharmacologics for an ability to prevent CD4+ down modulation (decrease in
25 expression of CD4+ on the cell surface) and HIV-1 expression.

A variety of compounds known to have antiviral properties against either acutely or chronically infected cells were evaluated for their ability to
30 inhibit HIV expression in these OM-10.1 cells. Several compounds that interact with biochemical pathways that may interfere with the activation process were also examined. The results of the evaluation were presented in a poster at the NCDDG/AIDS, San Diego, CA,
35 November 3-7 (1991). Among some 48 compounds evaluated, 3'-fluoro-3'-deoxythymidine (FLT),

- 6 -

interferon γ , and desferrioxamine were considered modest inhibitors of the activation of HIV-1.

5 The compounds of the present invention are known and disclosed in U.S. Patent No. 5,208,253 issued to Boschelli, et al., on May 4, 1993. The compounds disclosed in this issued patent are useful as agents which block leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases. The disclosure of this
10 issued patent is hereby incorporated by reference.

There is no disclosure in the above-identified reference to suggest the use of the compounds identified in this present application as anti-HIV or anti-HIV activating materials, as immunosuppressives,
15 and for the treatment of other diseases of the immune system.

SUMMARY

20 The present invention offers novel therapeutic strategies for the treatment of infection by the human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as the lethal immunosuppression (AIDS) experienced by those
25 individuals infected with the human immunodeficiency virus (HIV). Treating AIDS or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection:
30 AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential further exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ
35 transplant, exchange of body fluids, bites, accidental

-7-

needle stick, or exposure to patient blood during surgery.

5 It has been found that certain compounds, their derivatives, and pharmaceutically acceptable salts thereof, intervene in the eventual progression of HIV from an asymptomatic state to an active, progressive, life-threatening immunosuppressive state. While not wishing to be bound by theory, the compounds are believed to inhibit agents which activate transcription from HIV integrated within or already excised from an infected mammalian DNA. In addition, it has been found that pharmaceutical compositions comprised of the
10 aforementioned compounds, their derivatives, and salts can intervene in the eventual progression of HIV from a clinically latent state to an active, progressive, life-threatening immunosuppressive state (AIDS or AIDS related complex). The administration of these compositions to mammals in need thereof will offer the opportunity to devise new therapies effective against
15 acute and chronic HIV infections.
20

The present invention employs the newly developed physiologic tissue culture cell-based model of latency, OM-10.1, to identify therapeutic compounds for an ability to prevent HIV activation (J. Virol.
25 1991;65:4645-4653). The identified therapeutic compounds selectively block cellular pathways involved in HIV activation. The development of these therapeutic compounds into pharmacologic agents offers the prospect of a prolonged asymptomatic clinical
30 period of latency.

BRIEF DESCRIPTION OF THE DRAWINGS

35 The invention is described by way of example with reference to the accompanying drawings wherein:

- 8 -

Figure 1 is a graph representing the reversal of HIV-1 induction as evidenced by inhibition of Supernatant Reverse Transcriptase Activity in OM-10.1 Induction Cultures by the following compounds:

5 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide and

 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide, 1-oxide.

10 Figure 2 is another graph representing the reversal of HIV-1 induction as evidenced by inhibition of Supernatant Reverse Transcriptase Activity in OM-10.1 Induction Cultures by the following compounds:

15 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide and

 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-, 1-oxide.

20 Figure 3 is still another graph representing the reversal of HIV-1 induction as evidenced by inhibition of Supernatant Reverse Transcriptase Activity in OM-10.1 Induction Cultures by the following compounds:

 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide and

25 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-, 1-oxide.

 Figure 4 is a graph representing the inhibition of CD4 Down-modulation in OM-10.1 Induction Cultures by the following compounds:

30 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide and

 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-, 1-oxide.

35 Figure 5 is a graph representing the return to a latent state of the OM-10.1 cultures treated with 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide.

-9-


Figure 6 is a graph representing the return to a latent state of the OM-10.1 cultures treated with 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-, 1-oxide.

5

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention discloses a number of compounds for use as inhibitors of HIV or inhibitors of the activation of HIV in HIV-infected individuals, as immunosuppressives, and for the treatment of other diseases of the immune system. As indicated previously, these compounds are known and their methods of preparation have been taught in U.S. Patent 5,208,253 issued to Boschelli, et al., on May 4, 1993. Specifically, compounds of the present invention are of the formula (I):

20



I

25

wherein

R₁ is lower alkyl, phenyl, or benzyl;

R₂ is hydrogen, lower alkyl, phenyl, benzyl, thiophene, (CH₂)_mQ, or phenyl, benzyl, or thiophene substituted with (CH₂)_mQ;

30

n is an integer from 0 to 2;

m is an integer from 0 to 6;

Q is CO₂R₇ where R₇ is hydrogen or lower alkyl; and

35

R₃, R₄, R₅, R₆ are independently hydrogen, halo, hydroxy, nitro, amino, lower alkyl, and lower alkoxy.

-10-

Lower alkyl and lower alkoxy mean a straight or branched alkyl or alkoxy group having one to four carbon atoms and includes, for example, methyl, ethyl, propyl, i-propyl, or otherwise referred to as (methyl)ethyl, and t-butyl or otherwise referred to as 1,1-(dimethyl)ethyl, and correspondingly, for example, methoxy, ethoxy, i-propoxy or otherwise referred to as 1-(methyl)ethoxy and the like.

The compounds of Formula I are capable of further forming both pharmaceutically acceptable acid addition and/or base salts. All of these forms are within the scope of the present invention.

Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glucamine (see, for example, Berge SM, et al.,

-11-

"Pharmaceutical Salts," Journal of Pharmaceutical Science 1977;66:1-19).

5 The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their
10 respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

15 Pharmaceutically acceptable base addition salts are formed with inorganic or organic bases, such as metal bases or amines, such as alkali and alkaline earth metal bases, e.g., hydroxides or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples
20 of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge SM, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science 1977;66:1-19).

25 The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form
30 may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but
35 otherwise the salts are equivalent to their respective free acid for purposes of the present invention.

-12-

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

For medical use, the amount required of a compound of Formula I or pharmacologically acceptable salt thereof to achieve a therapeutic effect will, of course, vary both with the particular compound, the route of administration, the mammal under treatment, and the particular disorder of disease concerned. A suitable dose of a compound of Formula I or pharmacologically acceptable salt thereof for a mammal suffering from, or likely to suffer from any condition as described hereinbefore is 0.1 μ g to 500 mg of the compound per kilogram body weight. In the case of systemic administration, the dose may be in the range of 0.5 to 500 mg of the compound per kilogram body weight, the most preferred dosage being 0.5 to 50 mg/kg of mammal body weight administered two to three times daily. In the case of topical administration, e.g., to the skin or eye, a suitable dose may be in the range 0.1 ng to 100 μ g of the compound per kilogram, typically about 0.1 μ g/kg.

In the case of oral dosing for the treatment or prophylaxis of HIV infections in general, due to any course, a suitable dose of a compound of Formula I or physiologically acceptable salt thereof, may be as specified in the preceding paragraph, but most preferably is from 1 mg to 10 mg of the compound per kilogram, the most preferred dosage being from 1 mg to 5 mg/kg of mammal body weight, for example, from 1 mg to 2 mg/kg.

It is understood that the ordinarily skilled physician or veterinarian will readily determine and

-13-

prescribe the effective amount of the compound to prevent or arrest the progress of the condition for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low doses at first, subsequently increasing the dose until a maximum response is obtained.

While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation comprising a compound of Formula I or a pharmacologically acceptable acid addition or base salt thereof and a pharmacologically acceptable carrier therefor. Such formulations constitute a further feature of the present invention.

The formulations, both for veterinary and for human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefor and optionally other therapeutic ingredient(s). The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

The formulations include those in a form suitable for oral, pulmonary, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), intraarticular, topical, nasal, or buccal administration. Such formulations are understood to include long-acting formulations known in the art.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods may include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or

-14-

both, and then, if necessary, shaping the product into the desired formulation.

Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compound of Formula I. In the tablet the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5 or 10 to about 70 percent of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, transdermal and transmucosal systems, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions, suspensions, and emulsions. As an example, water or water-propylene glycol solutions may be mentioned for parenteral injection. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can

-15-

be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the

5 finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose and other well-known suspending agents. Preferably, the pharmaceutical preparation is in unit dosage form. In

10 such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets,

15 capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself or it can be the appropriate number of any of these in packaged form.

Particularly, the present invention is the use of

20 the following compounds in their free form or as pharmaceutically acceptable salts to substantially inhibit HIV or substantially inhibit the activation of HIV in an HIV-infected individual by administering an effective amount in unit dosage form of:

25 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;
3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;
5-chloro-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

30 5-methyl-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;
3-(1-methylethoxy)-5-nitrobenzo[b]thiophene-2-carboxamide;
7-methoxy-3-(1-methylethoxy)benzo[b]thiophene-

35 2-carboxamide;
3,5-dimethoxybenzo[b]thiophene-2-carboxamide;

-16-

- 5-methoxy-3-(phenylmethoxy)benzo[b]thiophene-
2-carboxamide;
- 5-methoxy-3-(phenoxy)benzo[b]thiophene-
2-carboxamide;
- 5 5-hydroxy-3-(1-methylethoxy)benzo[b]thiophene-
2-carboxamide;
- 6-methoxy-3-(1-methylethoxy)benzo[b]thiophene-
2-carboxamide;
- 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
10 2-yl]carbonyl]amino]benzoic acid;
- 3-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
2-yl]carbonyl]amino]benzoic acid;
- ethyl 2-[[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]benzeneacetate;
- 15 2-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
2-yl]carbonyl]amino]benzoic acid;
- 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
2-yl]carbonyl]aminomethyl]benzoic acid;
- methyl 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]-
20 thien-2-yl]carbonyl]amino]benzeneacetate;
- 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
2-yl]carbonyl]amino]benzeneacetic acid;
- methyl 3-[[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]benzeneacetate;
- 25 3-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
2-yl]carbonyl]amino]benzeneacetic acid;
- methyl 5-[[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]pentanoate;
- 5-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
30 2-yl]carbonyl]amino]pentanoic acid;
- 3-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-
2-yl]carbonyl]amino-2-thiophenecarboxylic acid;
- 5-methoxy-N-methyl-(3-(1-methylethoxy)benzo[b]-
thiophene-2-carboxamide;
- 35 N-ethyl-(5-methoxy-3-(1-methylethoxy)benzo[b]-
thiophene-2-carboxamide;

-17-

5-methoxy-3-(1-methylethoxy)-N-phenylbenzo[b]-thiophene-2-carboxamide;

5-methoxy-3-(1-methylethoxy)-N-(phenylmethyl)-benzo[b]thiophene-2-carboxamide;

5 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-1-oxide;

5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide 1,1'-dioxide;

10 3-(1,1-dimethylethoxy)-5-methoxybenzo[b]thiophene-2-carboxamide;

6-chloro-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

5-amino-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

15 methyl 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]butanoate;

4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]butanoic acid; or

20 5-methoxy-3-(1-methylethoxy)-N-(1-methylethyl)-benzo[b]thiophene-2-carboxamide.

The foregoing compounds of general Formula I can be used in the form of the isomeric mixtures or can optionally be separated by known separation processes, such as crystallization or chromatography. Compounds
25 of general Formula I which have a chiral centre can be used as stereoisomeric mixtures or in the form of the enantiomers. The enantiomers can be obtained by the processes conventionally used for the separation of stereoisomers.

30 It is indicated that the compounds of the present invention may be used to inhibit HIV or inhibit the activation of HIV in HIV-infected individuals. Preferably, the compounds of the present invention are used to inhibit HIV-1 or the activation of HIV-1 in
35 HIV-infected individuals. Nevertheless, the use of the compounds of the present invention is not limited to

-18-

treating HIV-1 infections and it should be understood that they may be used to treat HIV-2, HIV-3, HTLV-1, HTLV-2, or HTLV-3 infections, and any other strains of HIV or HTLV whose asymptomatic period would be extended or prolonged by the compounds of the present invention which substantially inhibit HIV or their activation in HIV-infected individuals.

In addition, the compounds may be administered to inhibit HIV in an acute infection as well as a chronic infection. Nevertheless, it is preferred that the compounds be administered to inhibit HIV in an acute infection.

It should further be understood that the present invention is also directed to combinations of the anti-HIV or anti-HIV activating compounds of this invention with one or more agents useful in the treatment of AIDS. For example, the compounds of this invention may be effectively administered in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art. It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives, or vaccines include in principle any combination with any pharmaceutical composition useful for the treatment of AIDS.

As used herein, the term "latent HIV" or individual infected with HIV in an "asymptomatic" state refers to the integration of human immunodeficiency viral or proviral DNA into host or mammalian genetic material concomitant with periods of substantially no viral expression. The length of time HIV is latent, or an individual is in an asymptomatic state, and non or substantially nonexpressive, varies with respect to such factors as age, gender, or race.

-19-

The term "expression" is relative. Complete expression has been defined as the basic scenario whereby HIV transcribes all viral proteins, assembles those proteins at lamellar membrane structures, and presents budding particle. It should be understood that as defined herein, the ability of the compounds of the present invention to prevent or substantially prevent complete expression constitutes the ability of the compounds to prevent or substantially prevent activation of HIV from a stage of nonexpression or latency.

The ability of the compounds of the present invention to prevent or substantially prevent the activation of HIV from a latent state can also be defined with regard to CD4 down modulation, and/or reverse transcriptase determinations, or other markers of HIV activity known to those of skill in the art such as protease activity.

Activation of HIV from a latent stage is associated with down modulation of the CD4 cell marker and increased reverse transcriptase activity for example. Use of the compounds of the present invention to treat HIV-infected cells inhibits or substantially inhibits CD4 down modulation and/or reverse transcriptase activity.

The usefulness of the compounds of the present invention as inhibitors HIV, inhibitors of the activation of latent HIV, as immunosuppressives, or in treating other immune diseases affecting an individual may be demonstrated by their effectiveness in various standard test procedures (see Feorino PM, et al., Antiviral Chemistry and Chemotherapy 1993;4(1):55-63 which is incorporated herein by reference). Specifically, the anti-latent HIV activator activity of the compounds having the Formula I of the present invention was determined by taking advantage of the

-20-

OM-10.1 cell line, described above, a unique
chronically-infected promyelocytic clone which remains
CD4+ until HIV-1 activation with tumor necrosis
factor- α or other cytokines known to those of skill in
5 the art to activate HIV-1.

The following nonlimiting examples illustrate the
preferred methods for using the compounds of the
invention.

10

EXAMPLES

The following examples illustrate techniques
discovered by the inventors for treating mammals
15 infected with HIV. It should be appreciated by those
of skill-in-the-art that the techniques disclosed in
the examples which follow represent laboratory
techniques discovered by the inventors to function well
in the practice of the invention, and thus can be
20 considered to constitute preferred modes for its
practice. Those of skill-in-the-art should, however,
in light of the present disclosure, appreciate that
many changes can be made in the specific embodiments
which are disclosed and still obtain a like or similar
25 result without departing from the spirit and scope of
the invention. In other words, the following examples
are given to illustrate particular compositions and
methods within the scope of the present invention and
are not intended to limit the scope of the present
30 invention.

EXAMPLE 1

Example 1 was performed as described by Butera ST,
et al., J. Virol. 1991;65:4645-4653. Test compounds
35 were first dissolved in 100% DMSO to the indicated
stock concentrations below in Table I. The stock

-21-

solution was then diluted in tissue culture starting at 1:100(10^{-2}) and proceeding on as indicated.

TABLE I

	Dilution	Test Compound A ¹	Test Compound B ²
5	[Stock]	20.0 mM	35.5 mM
	1:2000	10.0 μ M	17.75 μ M
	1:4000	5.0 μ M	8.88 μ M
	1:8000	2.5 μ M	4.44 μ M
10	1:16,000	1.25 μ M	2.22 μ M
	1:32,000	0.62 μ M	1.11 μ M
	1:64,000	0.31 μ M	0.55 μ M
	1:128,000	0.16 μ M	0.28 μ M
	1:256,000	78.0 nM	0.14 μ M
15	1:512,000	39.0 nM	70.0 nM
	1:10 ⁶	19.5 nM	35.0 nM

¹ Test Compound A - 5-methoxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide,

² Test Compound B - 5-methoxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide-, 1-oxide

OM-10.1 cells were then pretreated for 4 hours with the test compounds prior to TNF- α induction. TNF- α was added at 20 U/ml and induced cells were examined at 24 hours for evidence of surface CD4 down-modulation, as an indication of viral activation. Cells were also harvested after 24 hours of TNF- α induction for drug toxicity, being labeled with ³H thymidine during the final 18 hours in culture. At 48 hours, cell-free culture supernatant was collected for reverse transcriptase determination, as a further verification of the extent of HIV-1 activation. CD4 surface staining for flow cytometry and reverse transcriptase analysis were performed as described.

Two of the compounds, 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide and 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-, 1-oxide, appeared to have anti-induction activity in the OM-10.1 cell system. This was especially true for

-22-

5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-, 1-oxide where concentrations between 10 and 1 μ M were effective at substantially inhibiting HIV-1 activation. Higher concentrations (20.0 μ M) of the tested compounds appeared to completely inhibit HIV-1 activation. Although host cellular toxicity must be taken into consideration, nearly complete inhibition was also evident by CD4⁺ analysis. The foregoing results are evidenced by the following Tables II-IV and accompanying Figures 1-4.

Table II details the mean reverse transcriptase cpm values obtained from an analysis of the OM-10.1 TNF- α induced cultures with Test Compounds A and B. The values are graphically represented in Figure 1.

Table III details the percent inhibition of the reverse transcriptase activity of OM-10.1 TNF- α induced cultures with Test Compounds A and B. The values are graphically represented in Figure 2.

Table IV details the stimulation index (SI) value of the reverse transcriptase activity of OM-10.1 TNF- α induced cultures with Test Compounds A and B. The SI value is a measure of activity that compares a TNF- α treated culture to a non-TNF- α treated medium culture for incorporation of radio labeled nucleotides by reverse transcriptase. The values are graphically represented in Figure 3.

Figure 4 is a graph representing the inhibition of CD4 down modulation in the OM-10.1 TNF- α induced cultures with Test Compounds A and B. The graph considers the percent of CD4-positive cells at various different concentrations of the test compounds.

-23-

TABLE II

	Dilution	Test Compound A	Test Compound B	TNF	Medium
5	1:2000	1,494	7,725	28,528	3625
	1:4000	2,322	15,984		
	1:8000	5,766	21,009		
	1:16,000	10,103	23,336		
	1:32,000	16,673	22,931		
10	1:64,000	21,941	28,334		
	1:128,000	26,642	27,480		
	1:256,000	25,905	25,257		
	1:512,000	27,334	28,085		
	1:10 ⁶	24,994	30,025		

TABLE III

	Dilution	Test Compound A	Test Compound B
15	1:2000	94.76	72.92
	1:4000	91.86	43.97
	1:8000	79.79	26.36
	1:16,000	64.59	18.20
	1:32,000	41.56	19.62
20	1:64,000	23.09	0.68
	1:128,000	6.61	3.67
	1:256,000	9.19	11.47
	1:512,000	4.19	1.55
	1:10 ⁶	12.39	0.00

TABLE IV

	Dilution	Test Compound A	Test Compound B	TNF
30	1:2000	0.41	2.13	7.87
	1:4000	0.64	4.41	
	1:8000	1.59	5.80	
	1:16,000	2.79	6.44	
	1:32,000	4.60	6.33	
35	1:64,000	6.05	7.82	
	1:128,000	7.35	7.58	
	1:256,000	7.15	6.97	
	1:512,000	7.54	7.75	
	1:10 ⁶	6.89	8.28	

-24-

EXAMPLE 2

Example 2 was conducted in a manner similar to Example 1. Unlike Example 1, however, OM-10.1 cells were pretreated for 24 hours with TNF- α , prior to the addition of the test compounds 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide (A) and 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide-, 1-oxide (B). Moreover, in Example 2 the experiment was extended through 96 hours after the removal of TNF- α . The results of Example 2 with respect to Test Compound A are shown below in Table V, reported in terms of percent CD4-positive cells, and illustrated graphically in Figure 5. The results of Example 2 with respect to Test Compound B are shown below in Table XI, reported in terms of percent CD4-positive cells, and illustrated graphically in Figure 6.

TABLE V

	T-24	T-0	24	48	72	96
Medium	89.0	4.0	4.6	16.4	39.5	62.6
10 μ M	89.0	4.0	10.8	76.4	87.2	98.0
2.5 μ M	89.0	4.0	31.4	96.1	97.1	98.0
0.5 μ M	89.0	4.0	6.9	42.8	68.0	93.1
TNF	89.0	4.0	2.4	5.0	7.4	9.7

TABLE VI

	T-24	T-0	24	48	72	96
Medium	89.0	4.0	4.6	16.4	39.5	62.6
10 μ M	89.0	4.0	33.5	96.5	97.6	98.7
2.5 μ M	89.0	4.0	10.9	57.3	76.6	95.9
0.5 μ M	89.0	4.0	5.3	20.6	47.9	75.1
TNF	89.0	4.0	2.4	5.0	7.4	9.7

-25-

As illustrated in Figures 5 and 6, treatment with the test compounds to TNF- α stimulated OM-10.1 cells quickly returned activated HIV-1 to a state of latency. At 48 hours, the return to latency induced by the test compounds was significant. The pattern did not change through 96 hours except that the medium culture continued to return to latency. The return to latency was evidenced by an accelerated return of surface CD4, and the data for Figures 5 and 6 was generated in terms of percent CD4-positive cells by flow cytometry.

EXAMPLE 3

Antiviral assays of acute HIV-1 infection were performed in H9 and MT-4 cell lines. Cultures were batch infected in 1 mL of RPMI 1640 media/10% fetal calf serum containing 10^7 cells and 10^5 infectious doses of HIV-1_{iiib}; for an effective multiplicity of infection of 0.01. After 2 hours of viral absorption, cells were washed once and plated in 96-well microtiter plates at a density of 10^4 cells per well. The test compound, 5-methoxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide, was added to produce the desired concentration of drug and 0.2% DMSO in a final volume of 200 μ L. Cultures were tested for inhibition of reverse transcriptase activity to evidence reversal of HIV-1 induction by a reverse transcriptase assay at 7 days postinfection. Results of the reverse transcriptase assay are listed below in Table XIII and reported in terms of IC₅₀ and TC₅₀ values.

TABLE XII

μ M	MT-4	H9
IC ₅₀	0.1	0.9
TC ₅₀	6.3	2.5

-26-

A detailed description of the drug preparation and dilution, plate format, XTT assay, reverse transcriptase assay, and data analysis can be found by reference to the protocol provided in J. Virol
5 1991;65:4645-4653. Additional references are as follows:

Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-1 carrying cells MT-2 and MT-4 and application in a plaque assay. Science
10 1985;229:563-566.

Pauwels R, DeClercq E, Desmyter, et al. Sensitive and rapid assay on MT-4 cells on MT-4 cells for detection of antiviral compounds against the AIDS virus. J. Virol. Methods 1987;16:171-185.

15 Mann D, O'Brien S, Gilbert D, et al. Origin of the HIV-susceptible human CD4⁺ cell line H9. AIDS Research and Human Retroviruses 5: 1989;253-255.


The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments
20 are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All
25 changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

What is claimed is:

-27-

CLAIMS

1. A method for substantially inhibiting HIV or the activation of HIV in an HIV-infected individual or suppressing the immune system which comprises administering a therapeutically effective amount of a compound of the following formula:



I

wherein

R_1 is lower alkyl, phenyl, or benzyl;

R_2 is hydrogen, lower alkyl, phenyl, benzyl, thiophene, $(CH_2)_mQ$, or phenyl, benzyl, or thiophene substituted with $(CH_2)_mQ$;

n is an integer from 0 to 2;

m is an integer from 0 to 6;

Q is CO_2R_7 where R_7 is hydrogen or lower alkyl; and

R_3 , R_4 , R_5 , R_6 are independently hydrogen, halo, hydroxy, nitro, amino, lower alkyl, and lower alkoxy

as well as of the pharmaceutically acceptable salts of compounds of general Formulas I.

2. The method as defined in Claim 1, wherein the method is for substantially inhibiting HIV-1 or the activation of HIV-1.

-28-

3. The method as defined in Claim 1 where the compound is:

5-hydroxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide.

4. The method as defined in Claim 1 where the compound is:

5-methoxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide.

5. The method as defined in Claim 1 where the compound is:

5-methoxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide-, 1-oxide.

6. The method as defined in Claim 1 where the compound is:

3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

5 5-chloro-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

5-methyl-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

10 3-(1-methylethoxy)-5-nitrobenzo[b]thiophene-2-carboxamide;

7-methoxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide;

3,5-dimethoxybenzo[b]thiophene-2-carboxamide;

15 5-methoxy-3-(phenylmethoxy)benzo[b]thiophene-2-carboxamide;

5-methoxy-3-(phenoxy)benzo[b]thiophene-2-carboxamide;

6-methoxy-3-(1-methylethoxy)benzo[b]-thiophene-2-carboxamide;

20 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]-thien-2-yl]carbonyl]amino]benzoic acid;

- 29 -

- 3- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]benzoic acid;
ethyl 2- [[[5-methoxy-3-(1-methylethoxy)-
25 benzo[b]thien-2-yl]carbonyl]amino]benzeneacetate;
2- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]benzoic acid;
4- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]aminomethyl]benzoic acid;
30 methyl 4- [[[5-methoxy-3-(1-methylethoxy)-
benzo[b]thien-2-yl]carbonyl]amino]benzeneacetate;
4- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]benzeneacetic acid;
methyl 3- [[[5-methoxy-3-(1-methylethoxy)-
35 benzo[b]thien-2-yl]carbonyl]amino]benzeneacetate;
3- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]benzeneacetic acid;
methyl 5- [[[5-methoxy-3-(1-methylethoxy)-
benzo[b]thien-2-yl]carbonyl]amino]pentanoate;
40 5- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]pentanoic acid;
3- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino-2-thiophenecarboxylic
acid;
45 5-methoxy-N-methyl-(3-(1-methylethoxy)-
benzo[b]thiophene-2-carboxamide;
N-ethyl-(5-methoxy-3-(1-methylethoxy)-
benzo[b]thiophene-2-carboxamide;
5-methoxy-3-(1-methylethoxy)-N-phenyl-
50 benzo[b]thiophene-2-carboxamide;
5-methoxy-3-(1-methylethoxy)-N-(phenyl-
methyl)benzo[b]thiophene-2-carboxamide;
5-methoxy-3-(1-methylethoxy)benzo[b]-
thiophene-2-carboxamide 1,1'-dioxide;
55 3-(1,1-dimethylethoxy)-5-methoxybenzo[b]-
thiophene-2-carboxamide;

-30-

6-chloro-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

5-amino-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;


methyl 4-[[[5-methoxy-3-(1-methylethoxy)-benzo[b]thien-2-yl]carbonyl]amino]butanoate;

4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]butanoic acid; or

5-methoxy-3-(1-methylethoxy)-N-(1-methylethyl)benzo[b]thiophene-2-carboxamide.

7. The method as defined in Claim 1 wherein the compound is administered to an HIV-infected individual along with a pharmaceutically acceptable carrier.

8. A method for substantially inhibiting the activation of HIV in an HIV-infected individual which comprises administering a therapeutically effective amount of a compound of the following Formula:



I

wherein

R_1 is lower alkyl, phenyl, or benzyl;

R_2 is hydrogen, lower alkyl, phenyl, benzyl, thiophene, $(CH_2)_mQ$, or phenyl, benzyl, or thiophene substituted with $(CH_2)_mQ$;

n is an integer from 0 to 2;

m is an integer from 0 to 6;

-31-

- 20 Q is CO₂R₇ where R₇ is hydrogen or lower
 alkyl; and
 R₃, R₄, R₅, R₆ are independently hydrogen,
 halo, hydroxy, nitro, amino, lower
 alkyl, and lower alkoxy
25 as well as of the pharmaceutically acceptable
 salts of compounds of general Formulas I.
9. A method as defined in Claim 8 wherein the method
 is for substantially inhibiting the activation of
 HIV-1.
10. The method as defined in Claim 8 where the
 compound is:
 5-methoxy-3-(1-methylethoxy)benzo[b]-
 thiophene-2-carboxamide.
11. The method as defined in Claim 8 where the
 compound is:
 5-methoxy-3-(1-methylethoxy)benzo[b]-
 thiophene-2-carboxamide-, 1-oxide.
12. The method as defined in Claim 8 where the
 compound is:
 5-hydroxy-3-(1-methylethoxy)benzo[b]-
 thiophene-2-carboxamide.
13. The method as defined in Claim 8 where the
 compound is:
 3-(1-methylethoxy)benzo[b]thiophene-
 2-carboxamide;
5 5-chloro-3-(1-methylethoxy)benzo[b]thiophene-
 2-carboxamide;
 5-methyl-3-(1-methylethoxy)benzo[b]thiophene-
 2-carboxamide;

- 32 -


- 10 3- (1-methylethoxy) -5-nitrobenzo [b] thiophene-
2-carboxamide;
 7-methoxy-3- (1-methylethoxy) benzo [b] -
thiophene-2-carboxamide;
 3,5-dimethoxybenzo [b] thiophene-2-carboxamide;
 5-methoxy-3- (phenylmethoxy) benzo [b] thiophene-
15 2-carboxamide;
 5-methoxy-3- (phenoxy) benzo [b] thiophene-
2-carboxamide;
 6-methoxy-3- (1-methylethoxy) benzo [b] -
thiophene-2-carboxamide;
20 4- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] amino] benzoic acid;
 3- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] amino] benzoic acid;
 ethyl 2- [[[5-methoxy-3- (1-methylethoxy) -
25 benzo [b] thien-2-yl] carbonyl] amino] benzeneacetate;
 2- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] amino] benzoic acid;
 4- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] aminomethyl] benzoic acid;
30 methyl 4- [[[5-methoxy-3- (1-methylethoxy) -
benzo [b] thien-2-yl] carbonyl] amino] benzeneacetate;
 4- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] amino] benzeneacetic acid;
 methyl 3- [[[5-methoxy-3- (1-methylethoxy) -
35 benzo [b] thien-2-yl] carbonyl] amino] benzeneacetate;
 3- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] amino] benzeneacetic acid;
 methyl 5- [[[5-methoxy-3- (1-methylethoxy) -
benzo [b] thien-2-yl] carbonyl] amino] pentanoate;
40 5- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] amino] pentanoic acid;
 3- [[[5-methoxy-3- (1-methylethoxy) benzo [b] -
thien-2-yl] carbonyl] amino-2-thiophenecarboxylic
acid;

- 33 -

- 45 5-methoxy-N-methyl-(3-(1-methylethoxy)-benzo[b]thiophene-2-carboxamide;
 N-ethyl-(5-methoxy-3-(1-methylethoxy)-benzo[b]thiophene-2-carboxamide;
 5-methoxy-3-(1-methylethoxy)-N-phenyl-
 50 benzo[b]thiophene-2-carboxamide;
 5-methoxy-3-(1-methylethoxy)-N-(phenylmethyl)benzo[b]thiophene-2-carboxamide;
 5-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide 1,1'-dioxide;
 55 3-(1,1-dimethylethoxy)-5-methoxybenzo[b]thiophene-2-carboxamide;
 6-chloro-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;
 5-amino-3-(1-methylethoxy)benzo[b]thiophene-
 60 2-carboxamide;
 methyl 4-[[[5-methoxy-3-(1-methylethoxy)-benzo[b]thien-2-yl]carbonyl]amino]butanoate;
 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]butanoic acid; or
 65 5-methoxy-3-(1-methylethoxy)-N-(1-methylethyl)benzo[b]thiophene-2-carboxamide.

14. The method as defined in Claim 8 wherein the compound is administered to an infected individual along with a pharmaceutically acceptable carrier.
15. A method for substantially inhibiting HIV in an acute HIV-infected individual which comprises administering a therapeutically effective amount of a compound of the following Formula:

5



I

-34-

10

wherein

- R_1 is lower alkyl, phenyl, or benzyl;
 R_2 is hydrogen, lower alkyl, phenyl, benzyl,
thiophene, $(CH_2)_mQ$, or phenyl, benzyl,
or thiophene substituted with $(CH_2)_mQ$;
 n is an integer from 0 to 2;
 m is an integer from 0 to 6;
 Q is CO_2R_7 where R_7 is hydrogen or lower
alkyl; and
 R_3, R_4, R_5, R_6 are independently hydrogen,
halo, hydroxy, nitro, amino, lower
alkyl, and lower alkoxy
as well as of the pharmaceutically acceptable
salts of compounds of general Formulas I.

15

20

16. A method as defined in Claim 15 wherein the method
is for substantially inhibiting the activation of
HIV-1.
17. The method as defined in Claim 15 where the
compound is:
5-methoxy-3-(1-methylethoxy)benzo[b]-
thiophene-2-carboxamide.
18. The method as defined in Claim 15 where the
compound is:
5-methoxy-3-(1-methylethoxy)benzo[b]-
thiophene-2-carboxamide-, 1-oxide.
19. The method as defined in Claim 15 where the
compound is:
5-hydroxy-3-(1-methylethoxy)benzo[b]-
thiophene-2-carboxamide.

-35-

20. The method as defined in Claim 15 where the compound is:

3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

5 5-chloro-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

5-methyl-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

10 3-(1-methylethoxy)-5-nitrobenzo[b]thiophene-2-carboxamide;

7-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

3,5-dimethoxybenzo[b]thiophene-2-carboxamide;

15 5-methoxy-3-(phenylmethoxy)benzo[b]thiophene-2-carboxamide;

5-methoxy-3-(phenoxy)benzo[b]thiophene-2-carboxamide;

6-methoxy-3-(1-methylethoxy)benzo[b]thiophene-2-carboxamide;

20 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]benzoic acid;

3-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]benzoic acid;

25 ethyl 2-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]benzeneacetate;

2-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]benzoic acid;

4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]aminomethyl]benzoic acid;

30 methyl 4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]benzeneacetate;

4-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]benzeneacetic acid;

35 methyl 3-[[[5-methoxy-3-(1-methylethoxy)benzo[b]thien-2-yl]carbonyl]amino]benzeneacetate;

-36-

- 3- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]benzeneacetic acid;
methyl 5- [[[5-methoxy-3-(1-methylethoxy)-
benzo[b]thien-2-yl]carbonyl]amino]pentanoate;
40 5- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]pentanoic acid;
3- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino-2-thiophenecarboxylic
acid;
45 5-methoxy-N-methyl-(3-(1-methylethoxy)-
benzo[b]thiophene-2-carboxamide;
N-ethyl-(5-methoxy-3-(1-methylethoxy)-
benzo[b]thiophene-2-carboxamide;
5-methoxy-3-(1-methylethoxy)-N-phenyl-
50 benzo[b]thiophene-2-carboxamide;
5-methoxy-3-(1-methylethoxy)-N-(phenyl-
methyl)benzo[b]thiophene-2-carboxamide;
5-methoxy-3-(1-methylethoxy)benzo[b]-
thiophene-2-carboxamide 1,1'-dioxide;
55 3-(1,1-dimethylethoxy)-5-methoxybenzo[b]-
thiophene-2-carboxamide;
6-chloro-3-(1-methylethoxy)benzo[b]thiophene-
2-carboxamide;
5-amino-3-(1-methylethoxy)benzo[b]thiophene-
60 2-carboxamide;
methyl 4- [[[5-methoxy-3-(1-methylethoxy)-
benzo[b]thien-2-yl]carbonyl]amino]butanoate;
4- [[[5-methoxy-3-(1-methylethoxy)benzo[b]-
thien-2-yl]carbonyl]amino]butanoic acid; or
65 5-methoxy-3-(1-methylethoxy)-N-(1-methyl-
ethyl)benzo[b]thiophene-2-carboxamide.

21. The method as defined in Claim 15 wherein the
compound is administered to an infected individual
along with a pharmaceutically acceptable carrier.

1/6




FIG. 1

2/6




FIG. 2

3/6




FIG. 3

4/6




FIG. 4

5/6




FIG. 5

6/6




FIG. 6

INTERNATIONAL SEARCH REPORT

International application No.

US 94/09011

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,5 208 243 (BOSCHELLI ET AL) 4 May 1993 cited in the application see the whole document ---	1-21
A	AGENTS AND ACTIONS vol. 34 , 1991 pages 53 - 5 DONG ET AL 'Inhibition of Interleukin-2 Production and Lymphocyte responsiveness by the Cell Activation Inhibitor, CI-959' see the whole document ---	1-21
A	EP,A,0 221 345 (WARNER-LAMBERT COMPANY) 13 May 1987 see page 1, line 27 - line 41; claim 1 -----	1-21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

12 December 1994

Date of mailing of the international search report

27. 12. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Uiber, P

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US 94/09011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5208243	04-05-93	FR-A- 2679906	05-02-93
		AU-B- 645704	20-01-94
		AU-A- 2067692	11-03-93
		EP-A- 0526342	03-02-93
		JP-A- 5208974	20-08-93
		NZ-A- 243783	26-07-94

EP-A-0221345	13-05-87	US-A- 4761424	02-08-88
		AU-B- 605747	24-01-91
		AU-A- 6328586	02-04-87
		JP-A- 62081369	14-04-87
		US-A- 4921871	01-05-90
		US-A- 4868195	19-09-89
US-A- 4868200	19-09-89		
